SILENCE THERAP. SP.ADR/1 Cash Flow-to-Debt Ratio
SILENCE THERAP. SP.ADR/1 cash flow-to-debt ratio. SILENCE THERAP. SP.ADR/1 (XRP2) has a Cash Flow-to-Debt Ratio of -0.25x as of December 2025, meaning its operating cash flow of €-17.29 Million could theoretically repay 0% of its total liabilities (€69.14 Million) in one year. See how financially flexible is SILENCE THERAP. SP.ADR/1 to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SILENCE THERAP. SP.ADR/1 (2021–2025)
Cash flow-to-debt ratio of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. Historical debt coverage capacity for SILENCE THERAP. SP.ADR/1 across 5 annual periods. Check SILENCE THERAP. SP.ADR/1 (XRP2) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SILENCE THERAP. SP.ADR/1 Cash Flow-to-Debt Ratio by Year (2021–2025)
SILENCE THERAP. SP.ADR/1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for SILENCE THERAP. SP.ADR/1. For the full cash flow conversion analysis, see XRP2 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.90x | €-62.27 Million | €69.14 Million | ▲ +8.6% |
| 2024 | -0.99x | €-67.64 Million | €68.61 Million | ▼ -94.2% |
| 2023 | -0.51x | €-49.46 Million | €97.45 Million | ▲ +8.0% |
| 2022 | -0.55x | €-57.04 Million | €103.38 Million | ▼ -810.7% |
| 2021 | 0.08x | €9.19 Million | €118.32 Million | — |